Smith Denver Johnson

Director Smith Denver Johnson buys 505,555 shares of IVFH at $0.30; stock down -83.8% from 52-week high; 3 other insiders also bought within 14 days.

Director Smith Denver Johnson purchased 505,555 shares at $0.30, increasing his holdings by 18.2% to 3,289,655 shares. This buy occurs while the stock trades at $0.38, down -83.8% from its 52-week high of $2.35, and follows a 30-day gain of +16.0% countered by a 90-day decline of -24.0%. Johnson's prior four trades at IVFH have been consistently well-timed at the 90-day mark, with three generating gains of 22.7%, 24.2%, and 19.3% respectively. Notably, the cluster pattern shows 3 other insiders also bought within the past 14 days, suggesting coordinated conviction at current depressed valuations. Fundamentally, the company reported net losses of $-1.7M on quarterly revenue of $16.4M with flat annual growth, presenting a backdrop of deteriorating financial performance.

Director Smith Denver Johnson bought 31,250 shares of IVFH at $1.60 on 2024-12-05 ($50.0K); 4th buy in sequence with 100% 90d win rate across track record.

Director Smith Denver Johnson purchased 31,250 shares at $1.60, bringing his post-transaction holdings to 2.78M shares, a net increase of 31,250 shares or +1.1%. This is the fourth open-market buy across his entire trading history, following a pattern of three prior purchases at IVFH in July and August 2023, all of which posted positive 90-day returns (8.3%, 24.2%, 15.4%, and 11.4% respectively). His cross-ticker track record shows an average 30-day return of +11.7% and 90-day return of +15.6% with a 100% win rate over the 90-day measurement window. The stock traded at $1.60 on the purchase date and now stands at $1.75, with recent momentum of +9.4% over 30 days and +28.7% over 90 days. However, the company's fundamentals present a mixed picture: it reported revenue of $17.0M in the latest quarter but was unprofitable over its most recent full fiscal year, with annual revenue contracting -9.8% year-over-year. The elevated P/E of 87.50 and market cap of $89.5M relative to current profitability require scrutiny into whether this accumulated open-market buying reflects confidence in a turnaround or exposure to execution risk in a contracting revenue environment.

Director Smith Denver Johnson buys 350,000 shares at $1.20 (now $1.40); 2 other insiders bought within 14 days

Smith Denver Johnson, a Director at Innovative Food Holdings Inc, purchased 350,000 shares at $1.20 on 2024-07-22, increasing his holdings to 2,752,850 shares (+14.6% increase). His prior two purchases at this ticker in August 2023 both showed positive 90-day returns (+3.4% and +19.3%), establishing a pattern of well-timed accumulation at IVFH. The cluster detail—2 other insiders also buying within the past 14 days—indicates coordinated director-level confidence. However, the company context is mixed: while the latest quarter shows $15.7M revenue and $1.4M net income, the company posted negative full-year net income and experienced -9.8% annual revenue decline, creating a tension between insider accumulation and deteriorating financial fundamentals that merits examination.